Economics: Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.

Main|Search|PHGKB





Last Posted: Jan 04, 2018

---

• Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.  
  García-Pérez Lidia et al. The European journal of health economics : HEPAC : health economics in prevention and care 2017 Dec
• Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.  
  Balentine Courtney J et al. Surgery 2018 Jan 163(1) 88-96
• Appropriateness of newborn screening for classic galactosaemia: a systematic review.  
  Varela-Lema L et al. Journal of inherited metabolic disease 2016 Sep 39(5) 633-49
• Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.  
  Monroe Glen R et al. Genetics in medicine : official journal of the American College of Medical Genetics 2016 Sep 18(9) 949-56
• Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.  
  Modell Vicki et al. Immunologic research 2016 Jun 64(3) 736-53
• PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.  
  Seror Valerie et al. Journal of medical screening 2016 Jun 23(2) 62-9

more